BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32785740)

  • 21. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
    Qiao J; Ma R; Peng X; He W
    World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
    Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
    Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
    Haroche J; Abla O
    Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erdheim-Chester Disease: a comprehensive review of the literature.
    Mazor RD; Manevich-Mazor M; Shoenfeld Y
    Orphanet J Rare Dis; 2013 Sep; 8():137. PubMed ID: 24011030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
    Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
    Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erdheim-Chester disease.
    Brychtová M; Vlachová M; Gregorová J; Krejčí M; Adam Z; Ševčíková S
    Klin Onkol; 2021; 34(6):434-439. PubMed ID: 34911328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in Understanding and Management of Erdheim-Chester Disease.
    Kulkarni AM; Gayam PKR; Aranjani JM
    Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Erdheim-Chester disease].
    Haroche J; Cohen-Aubart F; Arnaud L; Hervier B; Charlotte F; Drier A; Gorochov G; Grenier PA; Cluzel P; Maksud P; Emile JF; Amoura Z
    Rev Med Interne; 2014 Nov; 35(11):715-22. PubMed ID: 24878295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
    Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
    Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging.
    Gray JCR; Kim J; Digianvittorio M; Feeley NK; Scheel PJ; Siegelman SS; Fishman EK; Rowe SP
    J Natl Compr Canc Netw; 2020 Jun; 18(6):650-655. PubMed ID: 32502983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective High-dose Interferon-α Therapy in a 13-Year-Old Girl With Erdheim-Chester Disease.
    Tezol O; Citak EC; Ayhan YS; Balci Y; Koc ZP; Yuyucu Karabulut Y
    J Pediatr Hematol Oncol; 2020 May; 42(4):326-331. PubMed ID: 31259822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
    Goyal G; Heaney ML; Collin M; Cohen-Aubart F; Vaglio A; Durham BH; Hershkovitz-Rokah O; Girschikofsky M; Jacobsen ED; Toyama K; Goodman AM; Hendrie P; Cao XX; Estrada-Veras JI; Shpilberg O; Abdo A; Kurokawa M; Dagna L; McClain KL; Mazor RD; Picarsic J; Janku F; Go RS; Haroche J; Diamond EL
    Blood; 2020 May; 135(22):1929-1945. PubMed ID: 32187362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erdheim-Chester disease: a systematic review.
    Cives M; Simone V; Rizzo FM; Dicuonzo F; Cristallo Lacalamita M; Ingravallo G; Silvestris F; Dammacco F
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):1-11. PubMed ID: 25744785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.